Table 5.
Comparison of biomarker expressions between LG ESS and ‘LG’ ULMS
| Score | (%) | OR (95% CI) | p Value | Sen (%) | Spe (%) | PPV (%) | NPV (%) | Acc (%) | |
|---|---|---|---|---|---|---|---|---|---|
| ER | <0.0001 | ||||||||
| ‘LG’ ULMS | ≥8 | 25.00 | 1 | ||||||
| LG ESS | ≥8 | 90.90 | 30.0 (3.36 to 268) | 52.60 | 96.40 | 90.90 | 75.00 | 78.70 | |
| PR | <0.0001 | ||||||||
| ‘LG’ ULMS | ≥8 | 17.20 | 1 | ||||||
| LG ESS | ≥8 | 77.80 | 16.8 (3.86 to 73.1) | 73.70 | 85.70 | 77.80 | 82.80 | 80.90 | |
| CD10 | 0.012 | ||||||||
| ‘LG’ ULMS | ≥8 | 24.10 | 1 | ||||||
| LG ESS | ≥8 | 64.70 | 5.76 (1.56 to 21.3) | 61.10 | 78.60 | 64.70 | 75.90 | 71.70 | |
| GEM | 0.22 | ||||||||
| ‘LG ULMS | ≤8 | 14.30 | 1 | ||||||
| LG ESS | ≤8 | 44.70 | 4.86 (0.53 to 44.3) | 94.40 | 22.20 | 44.70 | 85.70 | 51.10 | |
| C-caldesmon | 0.033 | ||||||||
| ‘LG’ ULMS | ≤8 | 22.70 | 1 | ||||||
| LG ESS | ≤8 | 56.50 | 4.42 (1.21 to 16.1) | 72.20 | 63.00 | 56.50 | 77.30 | 66.70 | |
| Transgelin | 0.034 | ||||||||
| ‘LG’ ULMS | ≤8 | 24.00 | 1 | ||||||
| LG ESS | ≤8 | 57.10 | 4.22 (1.20 to 14.9) | 66.70 | 67.90 | 57.10 | 76.00 | 67.40 | |
| SMA | 0.11 | ||||||||
| ‘LG’ ULMS | ≤8 | 30.00 | 1 | ||||||
| LG ESS | ≤8 | 60.00 | 3.50 (0.96 to 12.8) | 50.00 | 77.80 | 60.00 | 70.00 | 66.70 | |
| ASC1 | 0.28 | ||||||||
| ‘LG’ ULMS | ≥8 | 22.20 | 1 | ||||||
| LG ESS | ≥8 | 44.70 | 2.83 (0.52 to 15.5) | 89.50 | 25.00 | 44.70 | 77.80 | 51.10 | |
| Desmin | 0.14 | ||||||||
| ‘LG’ ULMS | ≤8 | 27.30 | 1 | ||||||
| LG ESS | ≤8 | 50.00 | 2.67 (0.78 to 9.15) | 66.70 | 57.10 | 50.00 | 72.70 | 60.90 | |
| Stathmin1 | 0.76 | ||||||||
| ‘LG’ ULMS | ≤8 | 37.00 | 1 | ||||||
| LG ESS | ≤8 | 44.40 | 1.36 (0.40 to 4.58) | 44.40 | 63.00% | 44.40 | 63.00 | 55.60 |
χ2 test for p values. Score represents composition score based on intensity and % expression.
Acc, accuracy; CD10, cluster of differentiation 10; ER, estrogen receptor; GEM, Guanosine-5′- triphosphate (GTP)-binding protein overexpressed in skeletal muscle; and ASC1, solute carrier family 7; LG ESS, low-grade endometrial stromal sarcoma; NPV, negative predictive value; PPV, positive predictive value; PR, progesterone receptor; Sen, sensitivity; SMA, smooth muscle actin; Spe, specificity; ULMS, uterine leiomyosarcoma.